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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.007Because recent studies implicate Toll-like receptors (TLRs) in the pathogenesis of fibrosis, we sought to
investigate the in vitro and in vivo role and mechanism of TLR4-mediated fibroblast responses in
fibrogenesis. We found that TLR4 was constitutively expressed, and accumulation of endogenous TLR4
ligands significantly elevated, in lesional skin and lung tissues from patients with scleroderma. Acti-
vation of TLR4 signaling in explanted fibroblasts resulted in enhanced collagen synthesis and increased
expression of multiple genes involved in tissue remodeling and extracellular matrix homeostasis.
Moreover, TLR4 dramatically enhanced the sensitivity of fibroblasts to the stimulatory effect of trans-
forming growth factor-b1. These profibrotic responses were abrogated by both genetic and pharmaco-
logical disruption of TLR4 signaling in vitro, and skin fibrosis induced by bleomycin in vivo was
attenuated in mice harboring a mutated TLR4. Activation of TLR4 in fibroblasts augmented the intensity
of canonical Smad signaling, and was accompanied by suppression of anti-fibrotic microRNA expression.
Together, these results suggest a novel model to account for persistent fibrogenesis in scleroderma, in
which activation of fibroblast TLR4 signaling, triggered by damage-associated endogenous TLR4 ligands,
results in augmented transforming growth factor-b1 sensitivity with increased matrix production and
progressive connective tissue remodeling. Under these conditions, fibroblast TLR4 serves as the switch
for converting self-limited tissue repair into intractable fibrosis. (Am J Pathol 2013, 182: 192e205;
http://dx.doi.org/10.1016/j.ajpath.2012.09.007)Supported by NIH grants AR-42309 and AR055240.Fibrosis, the hallmark of scleroderma or systemic sclerosis,
is a complex and dynamic pathophysiological process in
which inﬂammatory cell inﬁltration and the release of
cytokines and growth factors results in ﬁbroblast activation
and enhanced extracellular matrix (ECM) synthesis and
deposition.1 In contrast to normal wound healing, which is
characterized by tightly regulated and self-limited ECM
remodeling, leading to tissue regeneration, pathological
ﬁbrosis is associated with unrestrained ECM deposition,stigative Pathology.
.culminating in the formation of an intractable scar. Trans-
forming growth factor (TGF)-b induces the full repertoire of
ﬁbrotic responses and plays a key role in both physiological
tissue repair and in pathogenesis of scleroderma and related
ﬁbrotic disorders.2 Although multiple intracellular signaling
pathways, DNA-binding factors, and transcriptional cofac-
tors are implicated in TGF-bemediated ﬁbrotic responses,
Role of TLR4 in Fibrosisthe cross talk among these complex networks and the nature
of their persistent deregulation in pathological inﬂammation
and ﬁbrosis remain poorly understood. Elucidation of how
the factors mediating the switch from self-limited repair to
intractable scar accumulation is essential for the design of
rational therapies to interrupt the process in scleroderma.
Toll-like receptors (TLRs) are evolutionarily conserved
pattern recognition receptors that play key roles in host
defenses from microbial pathogens.3 Some TLRs (TLR2,
TLR4, TLR5, and TLR6) are expressed at the cell surface,
whereas others (TLR3, TLR7, TLR8, and TLR9) are nor-
mally found in intracellular vesicles.4 TLR signaling trig-
gered by pathogen-associated molecular patterns is mediated
by the cytoplasmic adaptor molecule, MyD88, and serine/
threonine kinases of the IL-1Reassociated kinase family,
resulting in translocation of NF-kB to the nucleus and
production of type I interferons and inﬂammatory cytokines.4
Aberrant TLR activation and signaling are increasingly linked
to a variety of inﬂammatory and autoimmune diseases.5,6
Toll-like receptor 4 was originally identiﬁed as the receptor
for lipopolysaccharide (LPS).7 On LPS binding, TLR4 forms
a complexwithmyeloid differentiation factor-2, resulting in the
recruitment of adaptor proteins to the intracellular Toll/IL-1
receptor domains.4 In addition to microbial pathogens, TLR4
can also be activated by endogenous ligands. One class of
endogenous ligands for TLR4 includes damage-associated
molecular patterns that are generated in situ as a consequence
of injury resulting in cell damage, ECM remodeling, autoim-
munity, and oxidative stress.8,9 Connective tissue molecules
[eg, hyaluronan, alternatively spliced ﬁbronectin extradomain
(Fn-EDA), tenascin C, and biglycan], cellular stress proteins
(eg, HMGB1 and gp96), and nucleic acids released from
necrotic cells can all bind to and activate TLR4. Endogenous
TLR4 ligands are implicated in a variety of diseases, and in
experimental ﬁbrosis in the kidney and liver.10e12 Moreover,
mice with genetic ablation of TLR4 are protected from
experimentally induced ﬁbrosis in these organs.13e15
However, the role of TLR4 in ﬁbrosis is controversial, with
some studies demonstrating that TLR4 contributes to the
resolution of postinﬂammatory ﬁbrogenesis.16
The present studies were undertaken to elucidate the
expression, mechanism of action, and potential involvement
of TLR4 in ﬁbrogenesis. The results reveal markedly
elevated expression of TLR4, together with increased
accumulation of endogenous TLR4 ligands, in lesional skin
and lung tissues from patients with scleroderma, and in mice
with bleomycin-induced experimental scleroderma. The
classic TLR4 ligand, LPS, induced stimulation of ECM gene
expression in explanted skin ﬁbroblasts in vitro, and
dramatically enhanced their ability to mount a proﬁbrotic
response when challenged with TGF-b1. These responses
were associated with augmented intensity of canonical
Smad signaling and suppression of anti-ﬁbrotic microRNAs
(miRNAs). Mice with a mutated TLR4 showed attenuated
skin ﬁbrosis in vivo when challenged with s.c. bleomycin.
Together, these results implicate innate immune signalingThe American Journal of Pathology - ajp.amjpathol.orgvia TLR4 in ﬁbroblast activation in scleroderma; they lead
us to propose a model for ﬁbrogenesis in which TLR4
signaling elicited by damage-associated endogenous TLR4
ligands within the ﬁbrotic milieu sensitizes stromal cells to
the proﬁbrotic activities of TGF-b1, resulting in enhanced
production and accumulation of ECM molecules. This, in
turn, establishes a positive feedback loop contributing to the
persistence and progression of ﬁbrosis.
Materials and Methods
Cell Culture and Reagents
Primary cultures of human skin ﬁbroblasts were established
by explantation from neonatal foreskin or from skin biopsy
specimens of the affected forearms of patients with sclero-
derma and the forearm of healthy adult volunteers and
studied at early passage.17 Human studies were performed
in accordance with protocols approved by the Institutional
Review Board for Human Studies at Northwestern Univer-
sity (Chicago, IL).
Mouse ﬁbroblast cultures were established from skin
biopsy specimens of 8-week-old female C3H/HeJ and C3H/
HeOuJ mice (Jackson Laboratories, Sacramento, CA) and
studied in parallel. Cultures were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal calf
serum (Gibco BRL, Grand Island, NY), 1% vitamin solu-
tions, and 2 mmol/L L-glutamine. All other tissue culture
reagents were from Lonza (Basel, Switzerland). For exper-
iments, cultures were placed in serum-free media containing
0.1% bovine serum albumin for 24 hours before the addition
of highly puriﬁed LPS (Sigma-Aldrich, St. Louis, MO) and
TGF-b1 (PeproTech, Rocky Hill, NJ). In selected experi-
ments, indicated concentrations of the selective TLR4
inhibitor, CLI-095 (InvivoGen, San Diego, CA), was added
to the cultures 30 minutes before LPS or TGF-b1.
qPCR
Levels of mRNA were determined by real-time quantitative
PCR (qPCR), as previously described.18 Brieﬂy, at the end of
each experiment, total RNAwas isolated from skin ﬁbroblasts
and reverse transcribed to cDNA using supermix (cDNA
Synthesis Supermix; Quanta Biosciences, Gaithersburg,
MD). The products (50 ng)were ampliﬁed using SYBRGreen
PCRMaster Mix (Applied Biosystems, Foster City, CA) with
primers shown in Table 1 on the Applied Biosystems 7500
Prism Sequence Detection System. Data were normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
RNA, and fold change is represented as follows: 2-DDCT
(2-[(CT
target -C
T
GAPDH)treatment - (C
T
target -C
T
GAPDH)non-treatment]).
miRNA Isolation and Quantitation by qPCR
miRNA was isolated from conﬂuent ﬁbroblasts using the mir-
Vana miRNA Isolation kit (Ambion/Applied Biosystems,193
Table 1 PCR Primers
Target gene Primer sequence
Human
aSMA
Forward 50-CAGGGCTGTTTTCCCATCCAT-30
Reverse 50-GCCATGTTCTATCGGGTACTTC-30
COL1A1
Forward 50-CCAGAAGAACTGGTACATCAGCA-30
Reverse 50-CGCCATACTCGAACTGGGAAT-30
COL1A2
Forward 50-GATGTTGAACTTGTTGCTGAGG-30
Reverse 50-TCTTTCCCCATTCATTTGTCTT-30
IL-6
Forward 50-AAATTCGGTACATCCTCGACGG-30
Reverse 50-GGAAGGTTCAGGTTGTTTTCTGC-30
IL-8
Forward 50-ACTGAGAGTGATTGAGAGTGGAC-30
Reverse 50-AACCCTCTGCACCCAGTTTTC-30
MCP-1
Forward 50-ACTGAAGCTCGTACTCTC-30
Reverse 50-CTTGGGTTGTGGAGTGAG-30
Mouse
aSMA
Forward 50-ATGCAGAAGGAGATCACAGC-30
Reverse 50-GTATTCCTGTTTGCTGATCCAC-30
COL1A1
Forward 50-AGCCGCAAAGAGTCTACATG-30
Reverse 50-CTTAGGCCATTGTGTATGCAG-30
COL1A2
Forward 50-CCGTGCTTCTCAGAACATCA-30
Reverse 50-CTTGCCCCATTCATTTGTCT-30
36B4
Forward 50-AGATGCAGCAGATCCGCAT-30
Reverse 50-GTTCTTGCCCATCAGCACC-30
Bhattacharyya et alFoster City, CA). Speciﬁc TaqMan probes for hsa-miR-29a,
hsa-miR-29b, hsa-miR-29c, and RNU24 (Applied Biosystems)
were used to measure miRNA expression levels using the
AppliedBiosystems 7500Prism SequenceDetection System.18
Genome-Wide Expression Profiling and Data Analysis
To examine responses induced by TLR4 activation at the
genome-wide level, conﬂuent ﬁbroblasts in serum-free media
were incubated with LPS for 6 hours, and RNA was isolated
using RNeasymini kits (Qiagen, Valencia, CA). The integrity
of RNA was ascertained using an Agilent Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA), and cDNA was labeled
using an Ambion labeling kit (Ambion) and hybridized to
Illumina human HT-12 version 4 Expression Microarray
Chips (Illumina, San Diego, CA), as previously described.19
Raw signal intensities for each probe were obtained using
Illumina Bead version 2 studio data analysis software and
imported to the Bioconductor lumi package for data trans-
formation and normalization.19e22 Probes with all samples
absent (near or lower than background levels) were ﬁltered.
To control for multiple testing and reduce the false-positive
rate (FDR), stringent statistical criteria were used to identify194differentially expressed genes with raw P < 0.01 and FDR-
adjusted P < 0.05.19
Western Blot Analysis
Whole cell lysates were prepared, and equal amounts of
proteins (20 to 50 mg per lane) were subjected toWestern blot
analysis using primary antibodies speciﬁc for type I collagen
(Southern Biotechnology, Birmingham, AL), phosphory-
lated Smad2 or Smad3 (both from Cell Signaling, Beverly,
MA), Smad1/2/3 (Santa-Cruz Biotechnology, Santa Cruz,
CA), tubulin (Sigma-Aldrich), and GAPDH (Invitrogen,
Carlsbad, CA), as previously described.19 Membranes were
then incubated with appropriate secondary antibodies and
subjected to enhanced chemiluminescence detection using an
electrochemiluminescent reagent (Pierce, Rockford, IL).
Transient Transfection Assays
The reporter constructs 772COL1A2-luc, harboring the
2772/58-bp fragment of the human proa1(I) collagen,
[SBE]4-luc harboring four tandem copies of the minimal
Smad-binding element,23 and NF-kB-luc were used in
transient transfection assays. Subconﬂuent cultures of skin
ﬁbroblasts in serum-free media were transfected using
Superfect reagent (Qiagen, Valencia, CA). After 24 hours of
incubation with TGF-b1 (5 or 10 ng/mL), cultures were
harvested and whole cell lysates were assayed for their
luciferase activities.24 In each experiment, ﬁbroblasts were
cotransfected with Renilla luciferase pRL-TK plasmids
(Promega, Madison, WI) as a control for transfection efﬁ-
ciency. Experiments were performed in triplicate and
repeated at least twice, with consistent results.
Immunofluorescence Microscopy of Explanted
Fibroblasts
Fibroblasts were incubated on eight-well Lab-Tek II chamber
glass slides (Nalgene Nunc International, Naperville, IL) in
serum-free Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 0.1% bovine serum albumin in the presence of
LPS (1mg/mL) and TGF-b (1 or 10 ng/mL) for 24 hours. Cells
were ﬁxed and permeabilized, and slides were incubated with
antibodies to type I collagen (Southern Biotechnology) or
a-smooth muscle actin (a-SMA; Sigma-Aldrich), at 1:100 or
1:1000 dilution, followed by Alexa Fluor secondary anti-
bodies (Invitrogen). Nuclei were identiﬁed using DAPI.
Subcellular distribution of immunoﬂuorescence was evalu-
ated under an immunoﬂuorescence microscope.24
IHC and Immunofluorescence Analysis of Skin and
Lung Biopsy Specimens
Skin biopsy specimens from 20 patients with scleroderma and
nine healthy volunteers, and lung biopsy specimens from four
patients with scleroderma with end-stage lung disease and fourajp.amjpathol.org - The American Journal of Pathology
Table 2 Clinical Characteristics of Patients
Patient no. Age (years) Sex SSc type Early/late* MRSS
Skin Immunostaining
SSc1 65 F dcSSC Early 12
SSc2 48 F dcSSc Early 21
SSc3 52 F dcSSc Early 13
SSc4 45 F dcSSc Early 9
SSc5 40 F dcSSc Early 32
SSc6 35 F dcSSc Early 10
SSc7 44 F dcSSc Early 12
SSc8 34 F dcSSc Late 32
SSc9 46 F dcSSc Late 35
SSc10 30 F dcSSc Late 4
SSc11 60 F lcSSc Late 4
SSc12 54 F dcSSc Late 13
SSc13 43 F dcSSc Early 9
SSc14 30 F dcSSc Late 18
SSc15 43 M dcSSc Early 34
SSc16 32 F dcSSc Early 31
SSc17 56 F dcSSc Early 13
SSc18 51 F dcSSc Early 11
SSc19 44 F dcSSc Early 20
SSc20 33 M dcSSc Early 13
Lung Immunostaining
SSc1 59 F NA Late
SSc2 46 M NA Late
SSc3 60 M lcSSc Late
SSc4 50 F dcSSc Late
*Early indicates <2 years from the first non-Raynaud’s disease
manifestation.
F, female; M, male; dcSSc, diffuse cutaneous SSc; lcSSc, limited cutaneous
SSc; MRSS, modified Rodnan skin score; NA, not available.
Role of TLR4 in Fibrosisnormal lungs were obtained in accordance with protocols
approved by the Institutional Review Boards for Human
Studies at Boston University (Boston, MA) and the University
of Pittsburgh (Pittsburgh, PA). Immunohistochemistry (IHC)
was performed on parafﬁn-embedded sections, as previously
described.17 Brieﬂy, after incubation of sections (4 mm thick)
with primary rabbit antibodies against TLR4 (1:100 dilution;
Abcam, Cambridge, MA), appropriate anti-rabbit or anti-
mouse IgG was applied as a secondary antibody. Bound anti-
bodiesweredetectedusing theDakoEnvisionþSystem(Santa
Clara, CA), according to the manufacturer’s instructions. To
quantify tissue levels of TLR4, immunopositive cells in four
randomly selected microscopic ﬁelds were counted by two
blinded examiners. To identify TLR4-positive cells in skin,
serial sections (4 mm thick) were incubated with primary anti-
bodies against TLR4 (1:50; Abcam), CD31 (1:50; Cell
Signaling, Beverly, MA), CD11B (1:100; BD Pharmingen,
San Jose, CA), and a-SMA (1:200; Sigma-Aldrich). Endoge-
nous TLR4 ligands were identiﬁed in the skin using antibodies
against Fn-EDA (1:50; Sigma-Aldrich) or tenascin C (1:50;
Abcam), followed by mouse Alexa Fluor or ﬂuorescein iso-
thiocyanateelabeled secondary antibodies (1:100; Invitrogen).
Hyaluronic acid (HA) in the tissue was identiﬁed using bio-
tinylated HA-binding protein (1:100; Calbiochem, San Diego,
CA). Nuclei were identiﬁed usingDAPI. Slidesweremounted,
evaluated, and photographed under a Zeiss UV Meta 510
confocalmicroscope (Carl Zeiss Inc., Jena,Germany). For lung
immunoﬂuorescence double labeling, parafﬁn-embedded
sections (6 mm thick) were incubated with primary antibodies
against TLR4 (1:50; Abcam) or a-SMA (1:200; Sigma-
Aldrich), followed by biotinylated rabbit or mouse secondary
antibodies (GE Healthcare Ltd, Little Chalfont, Buck-
inghamshire, UK), as previously described.25 After washing
with PBS, sections were incubated with avidin-conjugated
Texas Red and Fluorescein DCS (20 mg/mL) (A-2006 and A-
1100; Vector Laboratories). Nuclei were detected using
aHoechst nuclear stain (Sigma-Aldrich). Imageswere captured
using an Olympus Provis Fluorescence microscope (Olympus
America Inc., Melville, NY). Each section was examined
independently by two investigators in a blinded manner.
TLR4 Expression in a Mouse Model of Scleroderma
To evaluate the role of TLR4 in skin ﬁbrosis in vivo, C3H/
HeJ mutant mice and wild-type (WT) C3H/HeOuJ control
mice (Jackson Laboratories, Sacramento, CA) were studied.
The C3H/HeJ strain of mice harbor a missense mutation in
the intracellular signaling domain of TLR4 that replaces
proline with histidine at position 712, resulting in hypo-
responsiveness to LPS.26 Eight-week-old female C3H/HeJ
mice and WT C3H/HeOuJ mice were given bleomycin (10
mg/kg per day) or PBS by daily s.c. injections.27 At 3 and
21 days after the initiation of the injections, mice were
sacriﬁced, skin and lungs were harvested, and sections of
parafﬁn-embedded tissues (4 mm thick) were stained with
H&E, Masson’s trichrome, or Picrosirius red.27 ForThe American Journal of Pathology - ajp.amjpathol.orgimmunoﬂuorescence, sections (4 mm thick) of skin were
incubated with mouse antibodies against Fn-EDA (1:100;
Sigma-Aldrich) or tenascin C (1:50; Abcam), followed by
Alexa Fluorelabeled mouse secondary antibodies. Nuclei
were detected using DAPI. Slides were mounted, and
immunoﬂuorescence was evaluated under a Zeiss UV Meta
510 confocal microscope. Each experimental group con-
sisted of at least three to ﬁve mice. Studies were performed
according to institutionally approved protocols and were in
compliance with the animal welfare guidelines of the
Northwestern University Animal Care and Use Committee.
Quantification of Tissue Collagen
Lesional skin biopsy samples were homogenized in 0.5mol/L
glacial acetic acid. After centrifugation at 8944  g for
15 minutes, supernatants were assayed in triplicate for
soluble collagen using Sircol Collagen Assay kits (Biocolor,
Newtown Abbey, Ireland).27
Statistical Analysis
Data are presented as mean  SD. A Student’s t-test was
used for comparisons between two groups. P < 0.05 was
considered signiﬁcant.195
Figure 1 Elevated TLR4 expression in scleroderma skin. A: Skin biopsy specimens from the lesional forearm of patients with scleroderma (n Z 19) and
forearms of healthy controls (n Z 8) were examined by IHC. Left panels: Representative images. Brown staining indicates TLR4-positive cells. Scale bars:
200 mm (top panels); 50 mm (bottom panels). Blue, hematoxylin counterstain. Right panel: Quantitation of dermal cell TLR4 staining. Each dot, number
(mean) of immune-positive spindle-shaped interstitial cells (fibroblast-like) from four separate microscopic fields per biopsy. B: Double-immunofluorescence
labeling using antibodies to TLR4 and CD31 or a-SMA, or stained with DAPI. Yellow, colocalization of two antibodies. Arrows, colocalization. Scale barZ 50
mm. C: Cell lysates from explanted skin fibroblasts from healthy controls (n Z 3) and patients with scleroderma (n Z 4) were subjected to Western blot
analysis using antibodies against TLR4 and type I collagen (Cgn I). Left panel: Representative immunoblots. Right panel: Quantitation of TLR4 levels. Values
represent the mean  SD, corrected for tubulin in each lane. D: Explanted healthy control (nZ 3) and scleroderma (nZ 3) fibroblasts were incubated with
CLI-095 (3 mmol/L) for 24 hours. RNA and protein were isolated and subjected to qPCR. Left panel: Mean  SD of triplicate determinations relative to levels
in untreated fibroblasts. Right panel: Western blot analysis. Values shown indicate relative levels corrected for tubulin in each lane. E: Immunofluorescence.
Antibodies to Fn-EDA or tenascin-C, or HA-binding protein, were used on skin biopsy specimens from healthy controls (nZ 3) and patients with scleroderma
(n Z 5). Scale bar Z 50 mm. *P < 0.05.
Table 3 Biological Processes with Differentially Expressed
Genes Belonging to Individual GO Categories Significantly
Enriched with LPS-Regulated Genes
GO terms LPS/control (P values)
Response to wounding 137 (3.63  106)
Response to organic substance 199 (2.89  1013)
Cell migration 111 (1.89  1012)
Defense response 133 (3.27  106)
Extracellular matrix organization 28 (2.19  107)
System development 387 (2.03  1013)
Programmed cell death 190 (4.21  109)
Response to cytokine stimulus 65 (7.25  109)
Inflammatory response 55 (P > 0.01)
Vasculature development 67 (2.98  107)
Cardiovascular system development 92 (5.5  108)
GO, gene ontology.
Bhattacharyya et alResults
Elevated Expression of TLR4 and Endogenous TLR4
Ligands in Scleroderma Skin and Lung
To characterize the expression of TLR4 in scleroderma, skin
biopsy specimens from 20 patients with scleroderma (19
with diffuse and 1 with limited cutaneous systemic scle-
rosis) and nine healthy controls matched for sex, age, and
biopsy site were studied in parallel. The clinical and
demographic features of the study subjects are shown in
Table 2. Fourteen of the patients had early disease. The
scleroderma skin biopsy specimens showed a variable
degree of dermal thickening and sclerosis, with a paucity of
inﬂammatory cell inﬁltrates (data not shown). IHC demon-
strated that, in contrast to healthy control biopsy specimens
that revealed little detectable TLR4, scleroderma biopsy196 ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Elevated TLR4 expression in scleroderma lungs. A: IHC of lung biopsy specimens from patients with scleroderma and pulmonary fibrosis (nZ 4)
and normal donor lungs (n Z 4). Left panels: Brown staining indicates TLR4-positive cells. Blue, hematoxylin counterstain. Scale bars: 200 mm (top
panels); 50 mm (bottom panels). Right panel: Quantitation of TLR4 staining. Each dot, number (mean) of immunopositive fibroblasts from four separate
microscopic fields per biopsy. B: Red, immunofluorescence using antibodies to TLR4; green, a-SMA; yellow, colocalization of the two antibodies (white
arrows). Mouse isotype antibodies were used as a negative control, and a Hoechst stain was used to detect nuclei. Scale bars: 200 mm (top panels); 50 mm
(bottom panels). *P < 0.05.
Role of TLR4 in Fibrosisspecimens showed TLR4 immunostaining in a signiﬁcant
proportion of ﬁbroblasts, and vascular cells, within the
lesional dermis (Figure 1A). Semiquantitative analysis of
dermal TLR4 expression conﬁrmed a signiﬁcant increase in
scleroderma biopsy specimens compared with healthy
controls (P < 0.05). Our data also showed an increased
expression of TLR4 in keratinocytes in scleroderma biopsy
specimens, suggesting that keratinocytes might be activated
via TLR4 and play a role in ﬁbroblast activation via
epidermal-dermal cross talk. Western blot analysis against
a TLR4 antibody demonstrated one single band showing
antibody speciﬁcity (data not shown).
To determine the identity of TLR4-immunopositive cells,
double-immunoﬂuorescence labeling was performed on ﬁveThe American Journal of Pathology - ajp.amjpathol.orgscleroderma and ﬁve healthy control skin biopsy specimens
in parallel. A substantial increase in the number of a-
SMAepositive interstitial cells throughout the dermis was
noted in each of the scleroderma skin biopsy specimens
compared with the control biopsy specimens, which showed
a-SMA immunoreactivity prominent in the perivascular
regions. Moreover, approximately 50% of the TLR4-
positive interstitial cells in the scleroderma dermis were
also positive for a-SMA. Modest TLR4 colocalization
(approximately 25%) with the prototype microvascular
endothelial cell marker, CD31, was detected (Figure 1B).
Only scant CD11b immunoreactivity was found in the
dermis from either control or scleroderma skin biopsy
specimens. However, macrophage contribution cannot beFigure 3 LPS sensitizes fibroblasts to TGF-b1
stimulation of profibrotic gene expression. Fibro-
blasts were incubated with TGF-b1 (10 ng/mL) in
the presence or absence of LPS for 24 hours. A:
Total RNA was examined by qPCR. Results,
normalized with GAPDH mRNA, are shown as the
mean  SD of triplicate determinations. B: Whole
cell lysates and culture supernatants were sub-
jected to Western blot analysis. Representative
immunoblots are shown. C: Fibroblasts were
immunostained with antibodies to type I collagen
(Cgn I) or a-SMA or stained with DAPI, and viewed
by immunofluorescence microscopy (top panels)
or laser-scanning confocal microscopy (bottom
panels). Original magnification, 400. D: Right
panel: Mean immunofluorescence intensity of
individual fibroblasts stained with a-SMA was
determined in five different microscopic fields.
Results are given as the mean  SD. *P < 0.05.
197
Figure 4 TLR4 stimulates collagen gene expression. Fibroblasts were
transiently transfected with constitutively active TLR4 (CD4TLR4) or
inactive TLR4 (P-H CD4TLR4), 772COL1A2-luc, or empty vector and incu-
bated with TGF-b1 for 24 hours. A: Total RNA was examined by qPCR.
Results, normalized with GAPDH, are the mean  SD of triplicate deter-
minations. Inset: Secreted type I collagen (Cgn I). Whole cell lysates were
assayed for their luciferase activities (B) or examined by using Western
blot analysis (C). The results of luciferase assays are normalized with
Renilla luciferase. mut, mutant.
Bhattacharyya et alexcluded, based on our results, because not all macrophages
expressed CD11b and, therefore, the overall identity of the
TLR4þ cells was not well established.
We next investigated TLR4 expression in explanted
early-passage scleroderma and healthy control skin ﬁbro-
blasts in parallel. Western blot analysis showed a 2.3-fold
(mean) increase in TLR4 protein expression in vitro that
was associated with elevated type I collagen levels in all
four scleroderma ﬁbroblast lines compared with control
ﬁbroblasts (Figure 1C and data not shown). To examine the
functional role of TLR4 in the ex vivoeactivated phenotype
of scleroderma ﬁbroblasts, cultures were incubated with the
potent TLR4 inhibitor, CLI-095, which blocked TLR4
signaling by binding to the intracellular signaling domain.
The results demonstrated that, although there was no
signiﬁcant decrease in COL1A2 and a-SMA mRNA levels
in healthy control ﬁbroblasts, an approximately 50%
reduction was seen in mRNA level in scleroderma ﬁbro-
blasts treated with CLI-095 (P < 0.05). Similarly, Western
blot analysis showed a comparable approximately 55%
decrease in type I collagen levels, with no signiﬁcant change
in the healthy control ﬁbroblasts (Figure 1D and data not
shown).
Molecules generated or released in situ on chronic tissue
injury could be recognized as damage-associated molecular
patterns that serve as endogenous TLR4 ligands. We198examined the expression of the ECM components Fn-EDA,
tenascin C, and HA, each of which is a potential TLR4
ligand, in scleroderma skin biopsy specimens. Immunoﬂu-
orescence and histochemistry results demonstrated that, in
contrast to healthy control biopsy specimens that had little
detectable Fn-EDA, tenascin C, or HA in the dermis,
a dramatic increase in the accumulation of each of these
three endogenous TLR4 ligands was noted in all ﬁve
scleroderma biopsy specimens examined (Figure 1E).
Pulmonary ﬁbrosis associated with myoﬁbroblast accu-
mulation was a common and devastating complication of
scleroderma. Normal donor lungs showed only a low level
of TLR4 expression by IHC (Figure 2A). In these biopsy
specimens, TLR4 was largely restricted to alveolar epithelial
lining cells and scattered intra-alveolar macrophages. In
marked contrast, lung biopsy specimens from all four
patients with scleroderma and pulmonary ﬁbrosis showed
strong intracellular TLR4 expression. Immunostaining in
these lungs was most prominent in parenchymal ﬁbroblasts
(Figure 2A) and inﬁltrating cells (Figure 2A) located at, or
adjacent to, ﬁbrotic loci. Semiquantitative analysis of TLR4
expression conﬁrmed a signiﬁcant increase in scleroderma
lung biopsy specimens compared with healthy controls (P <
0.05). Numerous TLR4-positive interstitial cells in the
ﬁbrotic stroma showed strong a-SMA staining, identifying
them as myoﬁbroblasts (Figure 2B). In contrast, only scant
TLR4 immunostaining was noted around vascular
structures.
TLR4 Signaling Induces Global Gene Expression
Changes in Skin Fibroblasts
Innate immune signaling via TLR4 was extensively char-
acterized in cells of the immune system.28 In contrast, the
expression, regulation, and function of TLR4 in mesen-
chymal cells have received scant attention. The presence of
an intact TLR4 signaling axis in skin ﬁbroblasts was ﬁrst
conﬁrmed by demonstrating potent stimulation of classic
TLR4-dependent inﬂammatory genes by the TLR4 ligand,
LPS (Supplemental Figure S1A and data not shown).
Moreover, transient transfection assays demonstrated
signiﬁcant LPS stimulation of NF-kB-luc activity in ﬁbro-
blasts, which was abrogated in the presence of the TLR4
inhibitor, CLI-095 (Supplemental Figure S1B and data not
shown). Endotoxin contamination in these experiments was
excluded as the cause of these TLR4 responses using the
natural LPS antagonist, polymyxin B (data not shown).
To assess the pattern of TLR4-induced gene expression
changes at the genome-wide level, conﬂuent healthy skin
ﬁbroblasts were incubated with the classic TLR4 ligand,
LPS. After 6 hours of incubation, total RNA was harvested
and processed for hybridizations to Illumina Human HT-12
microarray chips containing >48,000 probes. Analysis of
the data demonstrated that LPS induced a broad pattern of
changes in gene expression in healthy ﬁbroblasts, with
a greater than twofold increase or decrease compared withajp.amjpathol.org - The American Journal of Pathology
Figure 5 LPS synergy with TGF-b1 is TLR4 dependent. A: Normal skin fibroblasts were incubated with LPS and TGF-b1 in the absence or presence of TLR4
inhibitors. Total RNA was examined by qPCR. B: Whole cell lysates and secreted proteins in the culture media were subjected to Western blot analysis. Type I
collagen (Cgn I) protein levels were quantitated. Values shown indicate relative levels corrected for GAPDH in each lane. C: Normal skin fibroblasts were
transfected with TLR4-specific siRNA or scrambled (Scr) control siRNA and incubated with LPS and TGF-b1 for 24 hours. Whole cell lysates were examined by
using Western blot analysis. Representative immunoblots. Cgn I levels were quantitated. Values shown indicate relative levels corrected for tubulin in each
lane. D and E: Skin fibroblasts from WT mice and TLR4-mutant (C3H/HeJ) mice were incubated in parallel with LPS and TGF-b1 for 24 hours. Whole cell lysates
were subjected to Western blot analysis (D). Fibroblasts were fixed, incubated with antibodies to a-SMA, and examined by immunofluorescence microscopy
(E). Blue, nuclei were identified by DAPI. Original magnification, 100. *P < 0.05.
Figure 6 TLR4 mediates fibrotic responses via enhanced Smad signaling. A: Normal skin fibroblasts transfected with TLR4-specific siRNA or scrambled
(Scr) control siRNA were incubated in media with LPS and TGF-b1 for 24 hours. Smad2/3 expression and phosphorylation were examined by using Western
blot analysis. Representative immunoblots are shown. Human (B) or WT (C3H/HeOuJ) and TLR4-mutant (C3H/HeJ) mouse skin fibroblasts (C) were trans-
fected with [SBE]4-luc in the presence of LPS and TGF-b1 for 24 hours, and cell lysates were assayed for their luciferase activities, normalized with Renilla
luciferase. Results, normalized with GAPDH, are shown as the mean  SD from triplicate determinations.
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Figure 7 TLR4 down-regulates antifibrotic miR-29. A: miRNA was
isolated and subjected to qPCR analysis. Results, expressed relative to
RNU24, are the mean  SD of triplicate determinations. B: Normal skin
fibroblasts were transfected with pre-miR-29b and incubated with LPS and
TGF-b1 for 24 hours. Cell lysates were examined by using Western blot
analysis. Representative immunoblots are shown. Cgn I, type I collagen.
Bhattacharyya et alvehicle-treated cultures (P < 0.01; FDR, 0.05) in the
expression of 342 and 271 genes up- and down-regulated,
respectively (Supplemental Table S1). Gene Ontology
analysis revealed signiﬁcant enrichment with LPS-regulated
genes in functional groups related to ECM synthesis and
wound healing (Table 3). Representative of this group were
genes encoding multiple collagens (COL1A1, COL3A1,
COL5A1, COL8A1, COL11A1, and COL12A1), mediators
of ﬁbrogenesis (plasminogen activator inhibitor-1, Wnt2
and Wnt5A, insulin-like growth factor binding protein 3,
and connective tissue growth factor), and the matricellular
proteins SPARC and periostin (Supplemental Figure S2).
Changes in the expression of multiple LPS-regulated genes
were conﬁrmed by qPCR (data not shown).200TLR4 Sensitizes Fibroblasts to Profibrotic Stimulation
by TGF-b1
The analysis of the microarray data indicated that in ﬁbro-
blasts, LPS prominently enhanced the expression of genes
related to ECM remodeling and ﬁbrogenesis. To examine
how TLR4 signaling modulated collagen gene expression in
stimulated skin ﬁbroblasts, cultures were incubated with
LPS in the presence or absence of TGF-b1. qPCR conﬁrmed
that LPS treatment by itself resulted in increased COL1A1
mRNA expression and type I collagen levels, which was
relatively modest compared with the increase induced by
TGF-b1 (Figure 3). However, LPS sensitized ﬁbroblasts to
TGF-b1 stimulation of collagen gene expression. Further-
more, although LPS alone had no signiﬁcant effect on a-
SMA expression, it markedly enhanced the stimulation
induced by TGF-b1 (Figure 3, C and D, and data not
shown).
To examine the effect of activated TLR4 on collagen gene
expression directly, ﬁbroblasts were transfected with
constitutively active TLR4. Ectopic expression of constitu-
tively active TLR4 was by itself sufﬁcient to induce
a signiﬁcant increase in COL1A1 mRNA and type I collagen
expression, as well as COL1A1-luc activity (Figure 4).
Remarkably, stimulation by TLR4 was further enhanced in
the presence of TGF-b1. As expected, ectopic TLR4 induced
a dose-dependent stimulation of NF-kB-luc activity (data not
shown). In contrast, transfection of ﬁbroblasts with a TLR4
mutant harboring a proline-to-histidine substitution within
the intracellular domain failed to stimulate COL1A2-luc
activity or type I collagen synthesis (Figure 4, B and C).
Moreover, the stimulatory effects of LPS on type I collagen
gene expression in TGF-b1eactivated ﬁbroblasts were
completely abrogated by pretreatment of the cultures with the
TLR4 inhibitor, CLI-095 (Figure 5, A and B).
LPS Fails to Synergize with TGF-b1 in the Absence of
Functional TLR4
The role of TLR4 in mediating LPS-induced ﬁbrotic
responses was further characterized using complementary
loss-of-function approaches. First, an RNA interference
approach was taken. Efﬁcient knockdown of TLR4 in
human skin ﬁbroblasts transfected with TLR4 small-
interfering RNA (siRNA) was accompanied by complete
loss of the synergistic effect of LPS on TGF-b1estimulated
collagen gene expression (Figure 5C). No change in Smad1/
2/3 was observed as an off-target effect. Next, primary skin
ﬁbroblasts explanted from TLR4-mutant C3H/HeJ mice and
WT control C3H/HeOuJ mice were incubated with LPS and
TGF-b1. Western blot and qPCR analysis showed that, in
contrast to WT control ﬁbroblasts, in TLR4-mutant ﬁbro-
blasts, LPS failed to synergize with TGF-b1 to stimulate
collagen or a-SMA gene expression or stress ﬁber incor-
poration (Figure 5, D and E, and data not shown). As ex-
pected, LPS also failed to stimulate IL-6 mRNA expression,ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Attenuated skin fibrosis in TLR4-
mutant mice. C3H/HeJ and WT mice, in parallel,
received daily s.c. injections of PBS or bleomycin
(Bleo) for up to 21 days. Mice were sacrificed, and
lesional skin was examined. A: Left panel: H&E
stain. Scale bar Z 200 mm. Middle panel: Mas-
son’s Trichrome stain. Scale barZ 200 mm. Right
panel: Dermal thickness. Results are the mean 
SD of triplicate determination from five mice per
group. Open bars, PBS; closed bars, Bleo. B: Pic-
rosirius red stain, viewed under polarized light.
Original magnification, 100. C: Immunofluores-
cence images are shown. Red arrows, a-SMA
epositive cells. *P < 0.05. Original magnifica-
tion, 400.
Role of TLR4 in Fibrosisconﬁrming the loss of functional TLR4 signaling in these
mutant ﬁbroblasts (data not shown). These complementary
genetic and pharmacological gain-of-function and loss-of-
function experiments collectively implicated TLR4 as both
sufﬁcient and necessary for synergistic stimulation of
collagen gene expression in ﬁbroblasts, establishing
a crucial functional role for TLR4 signaling in augmenting
the TGF-b1edependent proﬁbrotic response.
TLR4 Enhances Smad Signaling Intensity
We next focused on the effect of TLR4 on canonical Smad
signaling, which was recognized as a fundamental mecha-
nism underlying proﬁbrotic TGF-b1 responses.29 Western
blot analysis indicated that, although LPS on its own had no
signiﬁcant effect on Smad2/3 phosphorylation, it enhanced
the stimulation induced by TGF-b1, whereas this effect was
substantially attenuated by TLR4-speciﬁc siRNA, or by
CLI-095 pretreatment (Figure 6A and data not shown). To
investigate the effect of LPS on Smad-dependent transcrip-
tion, ﬁbroblasts were transiently transfected with [SBE]4-luc.
Incubation of transfected ﬁbroblasts with TGF-b1 in the
presence of LPS resulted in signiﬁcantly enhanced stimula-
tion of Smad-responsive reporter activity compared with
TGF-b1 alone (Figure 6B). Moreover, in contrast to WT
ﬁbroblasts, in TLR4-mutant ﬁbroblasts, LPS failed to further
enhance the stimulatory effect of TGF-b1 (Figure 6C).
Collectively, these results indicated that TLR4 signaling in
ﬁbroblasts directly affected the canonical Smad pathway of
TGF-b1 signaling.The American Journal of Pathology - ajp.amjpathol.orgIn search of mechanisms underlying the TLR4-mediated
ampliﬁcation of Smad signaling, we initially focused on the
TGF-b1 pseudoreceptor, bone morphogenetic protein, and
activin membrane-bound inhibitor (BAMBI), which nega-
tively modulated TGF-b1 responses and were previously
implicated in TLR4 signaling.13 In normal skin ﬁbroblasts,
LPS caused a time-dependent decrease in BAMBI that was
abrogated by CLI-095, or by knockdown or genetic loss of
TLR4 (data not shown). Because loss of BAMBI ampliﬁed
the intensity of Smad-mediated TGF-b1 responses,30 down-
regulation of BAMBI levels in response to TLR4 activation
observed in these experiments might at least, in part, be
responsible for LPS sensitizing ﬁbroblasts to TGF-b1.
TLR4 Suppresses Anti-Fibrotic miR-29 Expression
Noncoding miRNAs regulated gene expression by binding to
the 30-untranslated region of target mRNAs and were
implicated in a variety of cellular responses. In light of
their emerging importance in collagen regulation, ECM
homeostasis, and ﬁbrogenesis,31,32 we investigated the effect
of LPS on miRNA levels, focusing on miR-29, which was
implicated in multiple ﬁbrosing conditions. The results of
qPCR analysis showed that all three miR-29 species (a, b, c)
were detected in unstimulated normal skin ﬁbroblasts.
Incubation with LPS resulted in a marked reduction in miR-
29 levels in both the presence or absence of TGF-b1
(Figure 7A). Most important, overexpression of pre-miR-29a
and pre-miR-29b in these ﬁbroblasts abrogated the syner-
gistic stimulation of collagen gene expression induced by201
Figure 9 Reduced fibrotic gene expression in TLR4-mutant mice. C3H/HeJ and WT mice received
daily s.c. injections of PBS or bleomycin (Bleo) for 21 days. Lesional skin was harvested and
analyzed. A: RNA was quantitated by qPCR. The results, normalized for 36B4, represent the mean 
SD of triplicate determinations from four mice per group. Open bars, PBS; closed bars, Bleo. B:
Collagen content determined by colorimetric assays. Results represent the mean  SD of triplicate
determinations from at least three mice per group. Open bars, PBS; closed bars, Bleo. C: Protein was
examined by using Western blot analysis. Cgn I, type I collagen. *P < 0.05.
Bhattacharyya et alLPS in the presence of TGF-b1, functionally implicating
miR-29 in sensitizing ﬁbroblasts to TGF-b1 in the presence
of LPS (Figure 7B and data not shown).Attenuated Dermal Fibrosis in TLR4-Mutant Mice
To investigate the biological role of TLR4 in the patho-
genesis of ﬁbrosis in vivo, scleroderma was induced in
TLR4-mutant C3H/HeJ mice and C3H/HeOuJ WT mice by
daily s.c. injections of bleomycin.27 At early time points,
a comparable increase in the numbers of skin-inﬁltrating
inﬂammatory cells, accompanied by increased inﬂamma-
tory cytokine production, was observed in both control
C3H/HeOuJ mice and TLR4-mutant mice.
At late time points (day 21) of bleomycin injections,
a considerable increase in dermal thickness (greater than
twofold; P < 0.05) and accumulation of densely packed
collagen bundles in the skin were evident in WT mice,
compared with only a modest (approximately 30%, P Z
0.11) increase in dermal thickness in C3H/HeJ mice
(Figure 8A). Moreover, red birefringent collagen ﬁber
accumulation and a-SMA expression in the lesional dermis
and s.c. layers were notably attenuated in TLR4-mutant
C3H/HeJ mice (Figure 8, B and C). qPCR and Sircol
assays showed that a bleomycin-induced increase in
collagen and a-SMA mRNA levels and collagen accumu-
lation in the skin were virtually absent in C3H/HeJ mice
(Figure 9). Examination of lungs showed no signiﬁcant
ﬁbrosis or interstitial collagen accumulation in either WT
C3H/OuJ or C3H/HeJ mutant mice. Interestingly, however,
emphysematous changes with enlarged alveoli were noted202in C3H/HeJ mice, as previously described (Supplemental
Figure S3).33
Immunoﬂuorescence demonstrated a dramatic increase in
the accumulation of the endogenous TLR4 ligands Fn-EDA
and tenascin C in the skin in both WT and TLR4-mutant
C3H/HeJ mice injected with bleomycin (Figure 10A). These
results demonstrated that mice with defective TLR4
signaling were protected from skin ﬁbrosis despite the
robust accumulation of damage-associated endogenous
TLR4 ligands, suggesting an important functional role of
TLR4 in sustaining pathological ﬁbrogenesis. The sche-
matic depicted in Figure 10B illustrated this proposed model
for a self-sustaining cycle of ﬁbrogenesis driven by
endogenous TLR4 ligand stimulation of ﬁbroblasts.
Discussion
The mechanisms underlying the persistence and progression
of ﬁbrosis in scleroderma remain poorly understood.
Emerging evidence suggests a role for innate immune
recognition signaling in wound healing and ﬁbrogenesis.34
Our present results show that levels of both TLR4 and
damage-associated endogenous TLR4 ligands were elevated
in skin and lung tissues from patients with scleroderma, and
ﬁbroblasts explanted from lesional skin showed elevated
TLR4 expression in vitro. The results provide evidence sup-
porting a role for TLR4 signaling induced by endogenous
TLR4 ligands in ﬁbroblast activation and persistent ﬁbro-
genesis. Activated TLR4 signaling in ﬁbroblasts induced
a genome-wide cellular response, with up-regulation of genes
involved in ECM synthesis, connective tissue remodeling,ajp.amjpathol.org - The American Journal of Pathology
Figure 10 A: Bleomycin (Bleo)-induced skin fibrosis is associated with
accumulation of endogenous TLR4 ligands. TLR4-mutant mice and WT mice
received daily s.c. injections of PBS or Bleo for 21 days. Lesional skin was
harvested and examined by immunofluorescence. Representative images are
shown. Originalmagnification,400.B: Cycle of fibrogenesis. Innate immune
signaling via TLR4 switches self-limited repair into sustained fibrogenesis.
Prolonged injury leads to tissue damage, and generation of endogenous TLR4
ligands, with activation of TLR4 and sustained fibroblast activation.
Role of TLR4 in Fibrosisand ﬁbrogenesis.Moreover, the TLR4 ligand, LPS, sensitized
ﬁbroblasts to the proﬁbrotic effects of TGF-b1, resulting in
a substantial synergistic stimulation of ﬁbrogenic response.
These LPS-induced stimulatory responses appeared to beThe American Journal of Pathology - ajp.amjpathol.orgpartially dependent on TLR4-mediated down-regulation of
the endogenous TGF-b1 antagonist, BAMBI, resulting in
unopposed Smad signaling, and suppression of the anti-
ﬁbrotic miR-29, causing exaggerated TGF-b1 responses
and progressive ﬁbrogenesis. Mutant mice with nonfunc-
tional TLR4 signaling failed to develop bleomycin-induced
skin ﬁbrosis. These ﬁndings, therefore, implicate TLR4 as
a novel ﬁbrotic mediator with a fundamental role in the
persistence and progression of pathological ﬁbrosis.
Toll-like receptors are expressed on both inﬂammatory and
parenchymal cells, and initiate immune responses when
activated by pathogen-associated molecular patterns.4 We
found constitutive TLR4 expression associated with ﬁbro-
blasts and vascular cells in the lesional dermis in scleroderma
skin biopsy specimens, and parenchymal ﬁbroblasts and
inﬁltrating inﬂammatory cells at or adjacent to ﬁbrotic loci in
lung biopsy specimens. Elevated expression of TLR4 has
been noted in diabetic nephropathy, chronic periodontitis, and
inﬂammatory bowel disease.35e37 In chronic inﬂammatory
conditions, TLR4 may be activated by damage-associated
endogenous ligands, such as Fn-EDA, HA, tenascin C, and
biglycan, that are generated in situ as a consequence of
chronic injury. TLR4 is also implicated in ﬁbrogenesis, and
mice lacking Fn-EDA and tenascin-C fail to develop ﬁbrosis
in the lung.38,39 We observed elevated TLR4 expression in
scleroderma skin, lungs, and explanted ﬁbroblasts.Moreover,
our results suggest that signaling through elevated TLR4may
contribute to the activated phenotype of explanted sclero-
derma ﬁbroblasts. The underlying mechanism is not known
and might be due, in part, to stimulation by endogenous
TLR4 ligands forming a self-amplifying positive feedback
loop, resulting in persistent progression of ﬁbrosis.
We demonstrated that activation of TLR4 signaling by
LPS in ﬁbroblasts elicited signiﬁcant global changes in gene
expression, with modulation of many genes involved in
ECM remodeling, tissue repair, and wound healing. In
contrast, LPS induced only a relatively modest effect on
inﬂammation-associated genes in ﬁbroblasts. In inﬂamma-
tory cells, LPS induces many genes associated with innate
immunity and inﬂammation40,41; thus, our results suggest
distinct roles for TLR4 signaling in inﬂammatory cells,
where it serves primarily to elicit a powerful non-speciﬁc
inﬂammatory response, versus parenchymal cells, where it
might serve primarily to promote robust tissue repair.
We found that LPS enhanced Smad2/3-dependent TGF-
b1 transcriptional responses in normal ﬁbroblasts through
TLR4. These ﬁndings are consistent with other reports
delineating a proﬁbrotic TLR4 response and enhanced Smad
activation.13
In contrast to our results, Kim and Kim42 showed that
LPS blocked TGF-beSmad signaling in RAW264.7 cells
by inducing Smad3 phosphorylation in the linker region.
This divergence of LPS responses might be related to the
cell speciﬁcity, with mesenchymal cells and ﬁbroblasts
showing positive cross talk between TLR4 and TGF-b,
whereas inhibitory cross talk is observed in inﬂammatory203
Bhattacharyya et alcells. LPS induced down-regulation of BAMBI, a member
of the TGF-b type I receptor family that lacks the intracel-
lular kinase domain.30 BAMBI inhibits TGF-b signaling by
forming a ternary complex with Smad7 and the type I
receptor, resulting in blockade of Smad3 activation.43
Down-regulation of BAMBI sensitized LPS-treated ﬁbro-
blasts to TGF-b signaling, resulting in increased Smad2/3
phosphorylation and Smad-driven transcriptional responses.
Our ﬁndings are consistent with those in LPS-treated
hepatic stellate cells.13
miRNAs are involved in the regulation of a broad range
of physiological and pathological processes.31,44 Recent
evidence suggests that miRNAs play important roles in
connective tissue regulation, wound healing, and patholog-
ical ﬁbrosis.31 In particular, miR-29 has potent effects on
collagen gene expression in normal and scleroderma ﬁbro-
blasts,32 and its expression is reduced in mouse models
of renal, pulmonary, and liver ﬁbrosis.45 Patients with
advanced liver cirrhosis showed signiﬁcantly reduced serum
and tissue levels of miR-29.46 In the present studies, we
found that LPS caused a potent decrease in miR-29
expression in normal ﬁbroblasts that was TLR4 depen-
dent. More important, rescuing miR-29 in LPS-treated
ﬁbroblasts abrogated the stimulation of collagen gene
expression in the presence of TGF-b1, directly implicating
repression of miR-29 as a contributor to exaggerated
response to TGF-b1.
A crucial role of TLR4 in ﬁbrogenesis was highlighted in
experiments with TLR4-mutant C3H/HeJ mice.7 In the
absence of functional TLR4 signaling, bleomycin-induced
ﬁbrosis was attenuated. Previous studies13e15 have impli-
cated TLR4 in hepatic ﬁbrosis after bile duct ligation and
renal ﬁbrosis after ureteral ligation. We also found that
bleomycin caused a dramatic accumulation of the endoge-
nous ligands Fn-EDA and tenascin-C in the dermis.
Endogenous TLR4 ligands have been previously implicated
in ﬁbrogenesis, and mice lacking Fn-EDA or tenascin-C fail
to develop ﬁbrosis when challenged with bleomycin.38,39
In summary, the present results indicate that the expres-
sion of both TLR4 and of its endogenous ligands is mark-
edly elevated in lesional skin and lungs from patients with
scleroderma. Stimulation of TLR4 in explanted normal
ﬁbroblasts was associated with the induction of many genes
involved in ECM remodeling and tissue repair, and
synergistic enhancement of TGF-b1emediated ﬁbrotic
responses. Although multiple mechanisms underlie these
proﬁbrotic effects of TLR4 in ﬁbroblasts, enhanced Smad
signaling with down-regulation of BAMBI and suppression
of miR-29, which normally limits the intensity and duration
of ﬁbrotic responses, appear to be prominent. The relative
deﬁciency of these physiological restraints on ﬁbroblast
activity associated with sustained TLR4 signaling might be
expected to result in exaggerated and persistent collagen
synthesis and myoﬁbroblast transition due to unopposed
TGF-b signaling. Thus, in a ﬁbrogenic milieu enriched
with TGF-b and endogenous TLR4 ligands, ﬁbroblasts204expressing elevated TLR4 are likely to engage in unre-
strained collagen synthesis, myoﬁbroblast transformation,
and related ﬁbrogenic responses contributing to progression
of ﬁbrosis. Because the ﬁbrogenic response itself contrib-
utes to further accumulation of endogenous TLR4 ligands in
the cellular environment, a self-sustaining feed-forward loop
might develop that underlies maintenance and progression
of ﬁbrosis. Disrupting persistent TLR4 signaling by target-
ing endogenous ligand accumulation or its interaction with
TLR4, or by blocking intracellular TLR4 signaling, repre-
sents a potential novel strategy for breaking the cycle of
progressive ﬁbrosis in scleroderma.Acknowledgments
We thank Ruslan Medzhitov (Howard Hughes Medical
Institute, Yale School of Medicine), Andrei E. Medvedev
(University of Maryland School of Medicine), and Robert P.
Schleimer (Northwestern University) for valuable reagents,
the Northwestern University Microarray Core and confocal
imaging facility core for technical assistance, and members
of the Varga laboratory for helpful discussions.Supplemental Data
Supplemental material for this article can be found at http://dx.
doi.org/10.1016/j.ajpath.2012.09.007.References
1. Bhattacharyya S, Wei J, Varga J: Understanding ﬁbrosis in systemic
sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheu-
matol 2011, 8:42e54
2. Varga J, Pasche B: Transforming growth factor beta as a therapeutic
target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200e206
3. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA: Phylogenetic
perspectives in innate immunity. Science 1999, 284:1313e1318
4. Kawai T, Akira S: The role of pattern-recognition receptors in innate
immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373e384
5. Huang QQ, Pope RM: The role of toll-like receptors in rheumatoid
arthritis. Curr Rheumatol Rep 2009, 11:357e364
6. Landreth GE, Reed-Geaghan EG: Toll-like receptors in Alzheimer’s
disease. Curr Top Microbiol Immunol 2009, 336:137e153
7. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X,
Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-
Castagnoli P, Layton B, Beutler B: Defective LPS signaling in
C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science
1998, 282:2085e2088
8. Miyake K: Innate immune sensing of pathogens and danger signals by
cell surface Toll-like receptors. Semin Immunol 2007, 19:3e10
9. Piccinini AM, Midwood KS: DAMPening inﬂammation by modu-
lating TLR signalling. Mediators Inﬂamm 2010, 2010. pii: 672395
10. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI,
Sharland AF, Chadban SJ: TLR4 activation mediates kidney ische-
mia/reperfusion injury. J Clin Invest 2007, 117:2847e2859
11. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H,
Jayawardana ST, Ikeda S, Okumura K, Ogawa H: The extra domain A
of ﬁbronectin stimulates murine mast cells via toll-like receptor 4.
J Leukoc Biol 2007, 82:657e665ajp.amjpathol.org - The American Journal of Pathology
Role of TLR4 in Fibrosis12. Erridge C: Endogenous ligands of TLR2 and TLR4: agonists or
assistants? J Leukoc Biol 2010, 87:989e999
13. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y,
Brenner DA, Schwabe RF: TLR4 enhances TGF-beta signaling and
hepatic ﬁbrosis. Nat Med 2007, 13:1324e1332
14. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N,
Luirink IK, van der Poll T, Florquin S, Leemans JC: TLR4 promotes
ﬁbrosis but attenuates tubular damage in progressive renal injury. J Am
Soc Nephrol 2010, 21:1299e1308
15. Campbell MT, Hile KL, Zhang H, Asanuma H, Vanderbrink BA,
Rink RR, Meldrum KK: Toll-like receptor 4: a novel signaling
pathway during renal ﬁbrogenesis. J Surg Res 2011, 168:e61ee69
16. Yang HZ, Wang JP, Mi S, Liu HZ, Cui B, Yan HM, Yan J, Li Z,
Liu H, Hua F, Lu W, Hu ZW: TLR4 activity is required in the reso-
lution of pulmonary inﬂammation and ﬁbrosis after acute and chronic
lung injury. Am J Pathol 2012, 180:275e292
17. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H,
LakosG,MoriY,ChangE,NihijimaC,TakeharaK,Feghali-BostwickC,
Varga J: Smad-independent transforming growth factor-beta regulation
of early growth response-1 and sustained expression in ﬁbrosis: impli-
cations for scleroderma. Am J Pathol 2008, 173:1085e1099
18. Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, Lin S, Del
Galdo F, Feghali-Bostwick CA, Varga J: The early growth response
gene Egr2 (Alias Krox20) is a novel transcriptional target of trans-
forming growth factor-b that is up-regulated in systemic sclerosis and
mediates proﬁbrotic responses. Am J Pathol 2011, 178:2077e2090
19. Bhattacharyya S, Sargent JL, Du P, Lin S, Tourtellotte WG,
Takehara K, Whitﬁeld ML, Varga J: Egr-1 induces a proﬁbrotic
injury/repair gene program associated with systemic sclerosis. PLoS
One 2011, 6:e23082
20. Du P, Kibbe WA, Lin SM: nuID: a universal naming scheme of
oligonucleotides for Illumina, Affymetrix, and other microarrays. Biol
Direct 2007, 2:16
21. Du P, Kibbe WA, Lin SM: lumi: a pipeline for processing Illumina
microarray. Bioinformatics 2008, 24:1547e1548
22. Lin SM, Du P, Huber W, Kibbe WA: Model-based variance-stabilizing
transformation for Illumina microarray data. Nucleic Acids Res 2008,
36:e11
23. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G,
Trojanowska M, Gilliam AC, Varga J: Fibroblast expression of the
coactivator p300 governs the intensity of proﬁbrotic response to
transforming growth factor beta. Arthritis Rheum 2005, 52:1248e1258
24. Bhattacharyya S, Wei J, Melichian DS, Milbrandt J, Takehara K,
Varga J: The transcriptional cofactor nab2 is induced by TGF-b and
suppresses ﬁbroblast activation: physiological roles and impaired
expression in scleroderma. PLoS One 2009, 4:e7620
25. Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr, Feghali-
Bostwick CA: Localized expression of tenascin in systemic sclerosis-
associated lung ﬁbrosis and its regulation by insulin-like growth
factor binding protein 3. Arthritis Rheum 2012, 64:272e280
26. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y,
Takeda K, Akira S: Cutting edge: Toll-like receptor 4 (TLR4)-deﬁcient
mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as
the Lps gene product. J Immunol 1999, 162:3749e3752
27. Wu M, Melichian DS, de la Garza M, Gruner K, Bhattacharyya S,
Barr L, Nair A, Shahrara S, Sporn PH, Mustoe TA, Tourtellotte WG,
Varga J: Essential roles for early growth response transcription factor
Egr-1 in tissue ﬁbrosis and wound healing. Am J Pathol 2009, 175:
1041e1055The American Journal of Pathology - ajp.amjpathol.org28. Fontana MF, Vance RE: Two signal models in innate immunity.
Immunol Rev 2011, 243:26e39
29. Varga J: Scleroderma and Smads: dysfunctional Smad family dynamics
culminating in ﬁbrosis. Arthritis Rheum 2002, 46:1703e1713
30. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H,
Massague J, Niehrs C: Silencing of TGF-beta signalling by the pseu-
doreceptor BAMBI. Nature 1999, 401:480e485
31. Pandit KV, Milosevic J, Kaminski N: MicroRNAs in idiopathic
pulmonary ﬁbrosis. Transl Res 2011, 157:191e199
32. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M,
Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S,
Distler O: MicroRNA-29, a key regulator of collagen expression in
systemic sclerosis. Arthritis Rheum 2010, 62:1733e1743
33. Zhang X, Shan P, Jiang G, Cohn L, Lee PJ: Toll-like receptor 4
deﬁciency causes pulmonary emphysema. J Clin Invest 2006, 116:
3050e3059
34. Meneghin A, Hogaboam CM: Infectious disease, the innate immune
response, and ﬁbrosis. J Clin Invest 2007, 117:530e538
35. Lin M, Yiu WH, Wu HJ, Chan LY, Leung JC, Au WS, Chan KW,
Lai KN, Tang SC: Toll-like receptor 4 promotes tubular inﬂammation
in diabetic nephropathy. J Am Soc Nephrol 2012, 23:86e102
36. Rojo-Botello NR, García-Hernández AL, Moreno-Fierros L: Expres-
sion of toll-like receptors 2, 4 and 9 is increased in gingival tissue from
patients with type 2 diabetes and chronic periodontitis. J Periodontal
Res 2012, 47:62e73
37. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM:
Differential expression of toll-like receptors in patients with irritable
bowel syndrome. Am J Gastroenterol 2011, 106:329e336
38. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, Wilke CA,
Flaherty KR, Martinez FJ, Tsui JL, Sheppard D, Baralle FE,
Toews GB, White ES: An essential role for ﬁbronectin extra type III
domain A in pulmonary ﬁbrosis. Am J Respir Crit Care Med 2008,
177:638e645
39. Carey WA, Taylor GD, Dean WB, Bristow JD: Tenascin-C deﬁciency
attenuates TGF-ss-mediated ﬁbrosis following murine lung injury. Am
J Physiol Lung Cell Mol Physiol 2010, 299:L785eL793
40. Jin P, Han TH, Ren J, Saunders S,Wang E,Marincola FM, StroncekDF:
Molecular signatures of maturing dendritic cells: implications for testing
the quality of dendritic cell therapies. J Transl Med 2010, 8:4
41. Ban JY, Kim BS, Kim SC, Kim DH, Chung JH: Microarray analysis of
gene expression proﬁles in response to treatment with melatonin in
lipopolysaccharide activated RAW 264.7 cells. Korean J Physiol
Pharmacol 2011, 15:23e29
42. Kim EY, Kim BC: Lipopolysaccharide inhibits transforming growth
factor-beta1-stimulated Smad6 expression by inducing phosphoryla-
tion of the linker region of Smad3 through a TLR4-IRAK1-ERK1/2
pathway. FEBS Lett 2011, 585:779e785
43. Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, Chen YG: Human
BAMBI cooperates with Smad7 to inhibit transforming growth factor-
beta signaling. J Biol Chem 2009, 284:30097e30104
44. Jinek M, Doudna JA: A three-dimensional view of the molecular
machinery of RNA interference. Nature 2009, 457:405e412
45. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY: Smad3-mediated
upregulation of miR-21 promotes renal ﬁbrosis. J Am Soc Nephrol
2011, 22:1668e1681
46. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H,
Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F,
Trautwein C, Luedde T: Micro-RNA proﬁling reveals a role for miR-
29 in human and murine liver ﬁbrosis. Hepatology 2011, 53:209e218205
